Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
John de Groot(The University of Texas MD Anderson Cancer Center), Amy B. Heimberger(Caris Life Sciences (United States))
Cited by 165
Related Papers
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
|Neuro-Oncology|2010|708
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
|JCI Insight|2016|454
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
|Neuro-Oncology|2017|427
Hypoxia Potentiates Glioma-Mediated Immunosuppression
|PLoS ONE|2011|219